389 related articles for article (PubMed ID: 21724302)
1. Dopaminergic agonists in Parkinson's disease.
Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
[TBL] [Abstract][Full Text] [Related]
2. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
3. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Zhou CQ; Zhang JW; Wang M; Peng GG
J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
[TBL] [Abstract][Full Text] [Related]
7. [Choosing a dopamine agonist in Parkinson's disease].
Bogucki A; Gajos A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S14-21. PubMed ID: 17941454
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
9. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
10. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
Stocchi F; Torti M; Fossati C
Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists in Parkinson's disease.
Yamamoto M; Schapira AH
Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
13. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Chen XT; Zhang Q; Wen SY; Chen FF; Zhou CQ
Eur J Neurol; 2023 Mar; 30(3):762-773. PubMed ID: 36380711
[TBL] [Abstract][Full Text] [Related]
15. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
16. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
Chung SJ; Kim JM; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
Expert Opin Pharmacother; 2015 May; 16(7):961-70. PubMed ID: 25846031
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
18. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
19. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
